The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.
You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.
We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.
We are interested in where in or outside the cell the gene product carries out its function.
We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.
Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.
The requested target is unambiguously human cyclin-dependent kinase 7 (CDK7; UniProt P50613), historically called MO15/p39 MO15, and not a similarly named protein from another organism. Human biochemical work identifies it as an approximately 39-kDa, 347-residue CDK-family kinase that complexes with cyclin H and MAT1 and co-purifies with human TFIIH and RNA-polymerase-II C-terminal-domain (CTD) kinase activity. This agrees with the supplied CMGC Ser/Thr kinase-family and protein-kinase-domain annotations. No conflicting gene identity was encountered. (adamczewski1996mat1cdk7and pages 1-2, adamczewski1996mat1cdk7and pages 2-2)
CDK7 has two tightly connected primary functions. First, the relatively free CDK-activating kinase (CAK) complex—CDK7–cyclin H–MAT1—phosphorylates activation-loop threonines of CDK1, CDK2, CDK4, and CDK6. Second, when CAK is incorporated into TFIIH, CDK7 phosphorylates the repeated CTD of RNA polymerase II, principally at Ser5 and Ser7, coordinating transcription initiation, promoter clearance, pausing, RNA capping, and later transcription-cycle events. Complex context is therefore central to substrate selection. (yankulov1997regulationofcdk7 pages 1-2, peissert2020structuralbasisfor pages 1-2, gong2024cdk7inbreast pages 1-2)
| Aspect | Best-supported annotation | Key evidence |
|---|---|---|
| Identity | Human CDK7 (UniProt P50613; MO15/p39), a ~39-kDa, 347-aa CMGC-family cyclin-dependent Ser/Thr kinase with a canonical protein-kinase domain. | Human HeLa-cell purification identified the 347-aa CDK7 polypeptide and showed co-purification with cyclin H, MAT1, TFIIH subunits, and CTD-kinase activity. |
| Catalytic chemistry | Transfers the γ-phosphate of ATP to serine or threonine residues: ATP + protein-OH → ADP + phosphoprotein. | Recombinant and purified complexes phosphorylate synthetic RNA-polymerase-II CTD repeats and conserved activation-loop threonines of CDKs. |
| Free CAK substrates | The CDK7–cyclin H–MAT1 CDK-activating kinase phosphorylates the T-loops of CDK1, CDK2, CDK4, and CDK6, enabling cell-cycle kinase activation. | Biochemical and cellular studies identify CDK1 Thr161, CDK2 Thr160, CDK4 Thr172, and CDK6 Thr177 as activating targets, linking CAK to G1/S and G2/M progression. |
| TFIIH substrate/function | Within TFIIH, CDK7 primarily phosphorylates Ser5 and Ser7 in the heptad-repeat CTD of RNA polymerase II, promoting promoter clearance and coordinating pausing, RNA capping, productive transcription, and termination. | Purified TFIIH and recombinant CAK directly phosphorylate CTD substrates; selective CDK7 inhibition increases promoter-proximal pausing and disrupts CTD-dependent recruitment of capping and transcription-processing factors. |
| Complex/regulation | CDK7 is activated and its substrate choice is shaped by cyclin H and MAT1; MAT1 stabilizes CAK and anchors it to TFIIH through XPB/XPD contacts. | Structural and mutational work shows cyclin H repositions the kinase C-helix, MAT1 stabilizes the activation loop, and complex context shifts preference among CDK T-loops, Pol-II CTD, and transcription factors. |
| Localization | Functions principally in the nucleus, in transcription preinitiation complexes and a free CAK pool; CDK7, cyclin H, MAT1, and p62 also concentrate in Cajal/coiled bodies, especially during G1/S. | Immunofluorescence in human cells demonstrated CDK7–MAT1 colocalization in coiled bodies surrounded by transcription foci, although those bodies were not themselves active transcription sites. |
| NER relationship | CDK7 belongs to TFIIH, but core nucleotide-excision-repair chemistry is executed mainly by XPB/XPD and other repair factors; CDK7 is not established as the lesion-processing enzyme. | Repair proteins and TFIIH helicases showed diffuse nucleoplasmic or damage-site localization rather than coiled-body enrichment; regulated MAT1-mediated CAK attachment supports separation of TFIIH kinase and repair functions. |
| 2023–2024 clinical translation | Selective CDK7 inhibitors remain experimental oncology agents. In the phase-I LY3405105 study, 54 patients received oral drug (43 QD; 11 TIW); 7 DLTs occurred, all QD; 35/54 (64.8%) had treatment-related adverse events; Tmax was 1–2 h, half-life was 15–19 h, and approximately 75% target occupancy at ≥15 mg QD was observed. The MTD was 20 mg QD. Stable disease occurred in 12/43 (27.9%) QD and 5/11 (45.5%) TIW patients, with no partial or complete responses; development stopped because of limited activity and a narrow therapeutic window. | The trial demonstrated target engagement but gastrointestinal toxicity, myelosuppression, fatigue, and asthenia without objective responses, underscoring the need for predictive biomarkers, rational combinations, and improved therapeutic selectivity. |
Table: Concise evidence-based functional annotation of human CDK7, spanning identity, catalytic roles, complexes, localization, pathways, and 2023–2024 clinical translation.
The target matches all mandatory identifiers:
Human TFIIH purification from HeLa extracts showed that CDK7, cyclin H, and MAT1 co-purify with XPB, XPD, p62, CTD-kinase activity, transcription activity, and nucleotide-excision-repair activity. Reciprocal immunoprecipitation and recombinant reconstitution established that these three proteins form a stable kinase module rather than merely co-occurring in a large preparation. (adamczewski1996mat1cdk7and pages 2-3, adamczewski1996mat1cdk7and pages 2-2)
CDK7 is an ATP-dependent protein Ser/Thr kinase. Its general reaction is:
ATP + protein-serine/threonine → ADP + phosphoprotein-serine/threonine.
The strongest direct substrate classes are:
CDK7 specificity is not adequately described by a short linear peptide motif alone. It is determined by assembly state and macromolecular recruitment. Cyclin H affects recognition of cell-cycle CDKs and the Pol-II CTD; MAT1 stabilizes CDK7–cyclin H, changes substrate preference, and links CAK to TFIIH through XPB/XPD contacts. Experimentally, adding MAT1 shifts activity toward the Pol-II CTD relative to CDK2, whereas integration into TFIIH favors transcription-machine substrates. (yankulov1997regulationofcdk7 pages 1-2, rimel2018theessentialand pages 5-9)
Thus, the most defensible annotation is complex-dependent dual-specificity at the substrate-class level: exposed T-loop threonines in CDK–cyclin substrates for cell-cycle activation, and CTD serines in promoter-bound Pol II when positioned by TFIIH/Mediator.
CDK7 first associates with cyclin H, then with MAT1 to form heterotrimeric CAK. Structural work shows that cyclin H moves the CDK7 C-helix toward the active site, while MAT1 stabilizes the activation loop in a hydrophobic pocket and supports complex integrity. Unlike many CDKs, CDK7 can achieve an active conformation without obligatory phosphorylation of its own T-loop because MAT1 structurally organizes that loop; CDK7 T-loop phosphorylation can nevertheless modulate stability and activity in particular contexts. (peissert2020structuralbasisfor pages 1-2, peissert2020structuralbasisfor pages 5-6)
MAT1 also serves as the physical bridge into TFIIH. Its latch/coiled-coil region contacts the XPD ARCH region and XPB, anchoring CAK to the horseshoe-shaped TFIIH core. Structural mobility of this kinase module probably enables it to reach Pol-II CTD repeats and other preinitiation-complex substrates. Mediator helps position the module near the Pol-II CTD and stimulates phosphorylation. (rimel2018theessentialand pages 5-9)
Free or non-TFIIH-associated CAK activates CDK4/6 during mitogen-responsive G1 progression, CDK2 during G1/S and S phase, and CDK1 before mitosis. Consequently, CDK7 inhibition can delay both G1-to-S progression and G2/M entry rather than producing a single universal cell-cycle phenotype. (gong2024cdk7inbreast pages 1-2, garralda2024aphasei pages 1-2)
This is a catalytic hierarchy rather than conventional receptor signaling: CDK7–cyclin H–MAT1 → T-loop phosphorylation of CDK4/6, CDK2, and CDK1 → RB/E2F-controlled S-phase entry and mitotic progression. CDK7 activity itself is relatively constant across the cell cycle in older biochemical measurements, indicating that substrate availability, localization, and complex assembly are major control points. (adamczewski1996mat1cdk7and pages 1-2)
In the nuclear Pol-II preinitiation complex, TFIIH uses XPB to open promoter DNA, while its CDK7 module phosphorylates Pol II after initiation. CTD Ser5/Ser7 phosphorylation weakens the unphosphorylated CTD’s interaction with Mediator, favors promoter clearance, and creates docking sites for RNA-capping and processing machinery. CDK7 therefore couples synthesis of the first RNA bases to remodeling of the transcription complex. (peissert2020structuralbasisfor pages 1-2, jordan1997thecdk7cyclinhmat1 pages 1-2, rimel2018theessentialand pages 5-9)
CDK7 also shapes promoter-proximal pausing. Selective inhibition increases paused Pol II at thousands of human genes, reduces DSIF recruitment, and interferes with activation of CDK9/P-TEFb. Because CDK9 and SPT5 promote pause release, CDK7 sits upstream of an initiation-to-elongation kinase cascade. (rimel2018theessentialand pages 12-16)
The downstream consequences include altered 5′ capping, elongation rate, splicing-associated Pol-II behavior, chromatin modifications, and termination. In human cells, CDK7 inhibition produces transcriptional read-through at gene ends and changes H3K4me3/H3K36me3 distributions. These are mechanistically plausible extensions of CTD and CDK9 phosphorylation, but not evidence that CDK7 directly phosphorylates every affected processing or chromatin factor. (rimel2018theessentialand pages 12-16)
TFIIH also functions in nucleotide-excision repair (NER), but CDK7 should not be annotated as the lesion-recognition helicase or incision enzyme. XPB and XPD provide the relevant ATPase/translocase and helicase functions, while XPG, XPF–ERCC1, and repair-synthesis factors execute incision and gap filling. CDK7 is best described as the regulatory kinase module of a multifunctional complex whose CAK attachment is remodeled between transcriptional and repair states. (jordan1997thecdk7cyclinhmat1 pages 1-2, rimel2018theessentialand pages 5-9)
The distinction is reinforced by localization: CDK7–cyclin H–MAT1 and p62 concentrate in coiled/Cajal bodies, whereas XPG, PCNA, XPB, and XPD did not show corresponding enrichment there; UV irradiation did not redirect the coiled-body CAK pool to repair foci. Accordingly, coiled bodies are unlikely to be NER sites. (jordan1997thecdk7cyclinhmat1 pages 1-2, jordan1997thecdk7cyclinhmat1 pages 5-6)
CDK7’s principal functional compartment is the nucleus, where it participates in soluble CAK, TFIIH, promoter-bound preinitiation complexes, and transcription-associated chromatin. Human immunofluorescence also detected CDK7, cyclin H, MAT1, and p62 in coiled bodies, now generally termed Cajal bodies. CDK7 and MAT1 colocalized there; cyclin-H enrichment was strongest in G1/S and diminished in G2. (jordan1997thecdk7cyclinhmat1 pages 1-2, jordan1997thecdk7cyclinhmat1 pages 5-6)
Cajal bodies were surrounded by active transcription foci but did not themselves incorporate labeled uridine. This suggests a storage, maturation, assembly, or trafficking compartment rather than the main site at which CDK7 phosphorylates promoter-bound Pol II. Some CAK can also occur outside holo-TFIIH, and earlier reviews report a possible cytoplasmic pool, but the best-established catalytic locations relevant to the requested function are nuclear. (jordan1997thecdk7cyclinhmat1 pages 1-2, rimel2018theessentialand pages 5-9)
CDK7 is being targeted primarily in oncology because one enzyme supports both cell-cycle CDK activation and transcription. Tumors dependent on short-lived oncogenic transcripts, enhancer/super-enhancer programs, MYC/MYCN, E2F, estrogen-receptor, or androgen-receptor signaling may be more vulnerable than normal tissues. In breast-cancer models, CDK7 inhibitors produce cell-cycle arrest, apoptosis, and transcriptional suppression in both triple-negative and hormone-receptor-positive disease and may cooperate with endocrine therapy or chemotherapy. These remain predominantly preclinical or early clinical applications, not approved standard care. (song2024cyclindependentkinase7 pages 1-2)
The contemporary inhibitor landscape includes covalent agents such as THZ1, SY-1365, and LY3405105 and noncovalent/reversible agents such as samuraciclib/CT7001, SY-5609, Q901, and XL102. ATP-site similarity across CDKs makes biochemical and cellular selectivity difficult, while irreversible binding can prolong inhibition but does not by itself guarantee a safe therapeutic window. (zhang2025recentadvancesin pages 2-4, sorno2023areviewon pages 26-29)
The most informative recent peer-reviewed test was the phase-I trial of oral covalent inhibitor LY3405105 (NCT03770494), published online 2 August 2023 and in The Oncologist 2024 issue: https://doi.org/10.1093/oncolo/oyad215. It enrolled 54 heavily pretreated patients with advanced solid tumors—43 receiving once-daily dosing and 11 three-times-weekly dosing. Seven dose-limiting toxicities occurred, all in daily-dose cohorts; 35/54 (64.8%) experienced at least one treatment-related adverse event. Frequent toxicities were gastrointestinal symptoms, fatigue/asthenia, anemia, thrombocytopenia, and other manifestations of myelosuppression. (garralda2024aphasei pages 1-2, garralda2024aphasei pages 2-3)
Median time to peak concentration was 1–2 hours, terminal half-life 15–19 hours, and target occupancy approached 75% at doses ≥15 mg once daily; 20 mg once daily was the maximum tolerated and recommended phase-II dose. Despite substantial engagement, the best response was stable disease in 12/43 (27.9%) daily-treated and 5/11 (45.5%) intermittently treated patients, with no partial or complete responses. Expansion was not opened, and development stopped because tolerable exposure produced limited activity and the therapeutic window was narrow. (garralda2024aphasei pages 1-2, garralda2024aphasei pages 6-8)
Other programs produced preliminary signals rather than definitive implementation. Samuraciclib data summarized in a later review included three partial responses and a 36.0% clinical-benefit rate (9/25) in post-CDK4/6-inhibitor HR-positive/HER2-negative breast cancer, whereas SY-1365 and LY3405105 were discontinued and several other agents remained in phase-I evaluation. (zhang2025recentadvancesin pages 1-2, zhang2025recentadvancesin pages 10-12)
The authoritative interpretation is that CDK7 is biologically validated but clinically not yet validated as a broadly effective single-agent target. The LY3405105 experience shows that peripheral/skin target occupancy does not ensure tumor regression: normal proliferative and transcription-dependent tissues impose gastrointestinal and marrow toxicity before sufficiently deep or sustained tumor-selective inhibition is necessarily achieved. Overlapping and compensatory CTD kinases—including CDK9, CDK12, and CDK13—further complicate pharmacodynamic interpretation. (garralda2024aphasei pages 8-9, garralda2024aphasei pages 1-2)
The most important research needs are therefore:
Human CDK7/P50613 is a nuclear CMGC-family Ser/Thr kinase whose defining function is to connect cell-cycle kinase activation with Pol-II transcription. As free CAK, it activates CDK1/2/4/6 by T-loop phosphorylation; as the kinase module of TFIIH, it phosphorylates Pol-II CTD Ser5/Ser7 and coordinates promoter clearance, pausing, RNA processing, and termination. Cyclin H, MAT1, TFIIH, and Mediator determine its activation, positioning, and substrate preference. Its presence in TFIIH associates it with NER, but the direct DNA-opening and lesion-processing chemistry belongs principally to other TFIIH and repair proteins. CDK7 inhibition remains a compelling experimental oncology strategy, yet 2023–2024 clinical evidence demonstrates a narrow therapeutic window and limited unselected single-agent activity, making biomarker-guided combinations and improved pharmacology the most credible path forward.
References
(adamczewski1996mat1cdk7and pages 1-2): J. P. Adamczewski, M. Rossignol, J. P. Tassan, E. A. Nigg, V. Moncollin, and J. M. Egly. Mat1, cdk7 and cyclin h form a kinase complex which is uv light‐sensitive upon association with tfiih. The EMBO Journal, 15:1877-1884, Apr 1996. URL: https://doi.org/10.1002/j.1460-2075.1996.tb00538.x, doi:10.1002/j.1460-2075.1996.tb00538.x. This article has 184 citations.
(adamczewski1996mat1cdk7and pages 2-2): J. P. Adamczewski, M. Rossignol, J. P. Tassan, E. A. Nigg, V. Moncollin, and J. M. Egly. Mat1, cdk7 and cyclin h form a kinase complex which is uv light‐sensitive upon association with tfiih. The EMBO Journal, 15:1877-1884, Apr 1996. URL: https://doi.org/10.1002/j.1460-2075.1996.tb00538.x, doi:10.1002/j.1460-2075.1996.tb00538.x. This article has 184 citations.
(yankulov1997regulationofcdk7 pages 1-2): KY Yankulov and DL Bentley. Regulation of cdk7 substrate specificity by mat1 and tfiih. The EMBO Journal, 16:1638-1646, Apr 1997. URL: https://doi.org/10.1093/emboj/16.7.1638, doi:10.1093/emboj/16.7.1638. This article has 258 citations.
(peissert2020structuralbasisfor pages 1-2): Stefan Peissert, Andreas Schlosser, Rafaela Kendel, Jochen Kuper, and Caroline Kisker. Structural basis for cdk7 activation by mat1 and cyclin h. Oct 2020. URL: https://doi.org/10.1073/pnas.2010885117, doi:10.1073/pnas.2010885117. This article has 69 citations and is from a highest quality peer-reviewed journal.
(gong2024cdk7inbreast pages 1-2): Ying Gong and Huiping Li. Cdk7 in breast cancer: mechanisms of action and therapeutic potential. Cell Communication and Signaling : CCS, Apr 2024. URL: https://doi.org/10.1186/s12964-024-01577-y, doi:10.1186/s12964-024-01577-y. This article has 29 citations.
(song2024cyclindependentkinase7 pages 1-2): Xue Song, Chen Fang, Yan Dai, Yang Sun, Chang Qiu, Xiaojie Lin, and Rui Xu. Cyclin-dependent kinase 7 (cdk7) inhibitors as a novel therapeutic strategy for different molecular types of breast cancer. British Journal of Cancer, 130(8):1239-1248, Feb 2024. URL: https://doi.org/10.1038/s41416-024-02589-8, doi:10.1038/s41416-024-02589-8. This article has 32 citations and is from a domain leading peer-reviewed journal.
(adamczewski1996mat1cdk7and pages 2-3): J. P. Adamczewski, M. Rossignol, J. P. Tassan, E. A. Nigg, V. Moncollin, and J. M. Egly. Mat1, cdk7 and cyclin h form a kinase complex which is uv light‐sensitive upon association with tfiih. The EMBO Journal, 15:1877-1884, Apr 1996. URL: https://doi.org/10.1002/j.1460-2075.1996.tb00538.x, doi:10.1002/j.1460-2075.1996.tb00538.x. This article has 184 citations.
(rimel2018theessentialand pages 12-16): Jenna K. Rimel and Dylan J. Taatjes. The essential and multifunctional tfiih complex. Protein Science : A Publication of the Protein Society, 27:1018-1037, Apr 2018. URL: https://doi.org/10.1002/pro.3424, doi:10.1002/pro.3424. This article has 199 citations.
(rimel2018theessentialand pages 5-9): Jenna K. Rimel and Dylan J. Taatjes. The essential and multifunctional tfiih complex. Protein Science : A Publication of the Protein Society, 27:1018-1037, Apr 2018. URL: https://doi.org/10.1002/pro.3424, doi:10.1002/pro.3424. This article has 199 citations.
(peissert2020structuralbasisfor pages 5-6): Stefan Peissert, Andreas Schlosser, Rafaela Kendel, Jochen Kuper, and Caroline Kisker. Structural basis for cdk7 activation by mat1 and cyclin h. Oct 2020. URL: https://doi.org/10.1073/pnas.2010885117, doi:10.1073/pnas.2010885117. This article has 69 citations and is from a highest quality peer-reviewed journal.
(garralda2024aphasei pages 1-2): Elena Garralda, Alison M Schram, Philippe L Bedard, Gary K Schwartz, Eunice Yuen, Samuel C McNeely, Silvia Ribeiro, Jason Cunningham, Yi Wang, Arantxa Urunuela, Xiaojian Xu, and Patricia LoRusso. A phase i dose-escalation study of ly3405105, a covalent inhibitor of cyclin-dependent kinase 7, administered to patients with advanced solid tumors. The Oncologist, 29:e131-e140, Aug 2024. URL: https://doi.org/10.1093/oncolo/oyad215, doi:10.1093/oncolo/oyad215. This article has 23 citations.
(jordan1997thecdk7cyclinhmat1 pages 1-2): P. Jordan, C. Cunha, and M. Carmo-Fonseca. The cdk7-cyclin h-mat1 complex associated with tfiih is localized in coiled bodies. Molecular biology of the cell, 8 7:1207-17, Jul 1997. URL: https://doi.org/10.1091/mbc.8.7.1207, doi:10.1091/mbc.8.7.1207. This article has 82 citations and is from a domain leading peer-reviewed journal.
(jordan1997thecdk7cyclinhmat1 pages 5-6): P. Jordan, C. Cunha, and M. Carmo-Fonseca. The cdk7-cyclin h-mat1 complex associated with tfiih is localized in coiled bodies. Molecular biology of the cell, 8 7:1207-17, Jul 1997. URL: https://doi.org/10.1091/mbc.8.7.1207, doi:10.1091/mbc.8.7.1207. This article has 82 citations and is from a domain leading peer-reviewed journal.
(zhang2025recentadvancesin pages 2-4): Lingzhi Zhang, Shiqin Yang, Zhe Guan, Liangyu Lei, Tingting Zhang, Ye Zhang, Xiangyang Miao, and Shiqi Wu. Recent advances in development of cdk7 inhibitors and their clinical trials: a narrative review. Sep 2025. URL: https://doi.org/10.21037/tcr-2025-81, doi:10.21037/tcr-2025-81. This article has 5 citations.
(sorno2023areviewon pages 26-29): RH Sorno. A review on cyclin-dependent kinase 7 (cdk7) inhibitors as anticancer agents. Unknown journal, 2023.
(garralda2024aphasei pages 2-3): Elena Garralda, Alison M Schram, Philippe L Bedard, Gary K Schwartz, Eunice Yuen, Samuel C McNeely, Silvia Ribeiro, Jason Cunningham, Yi Wang, Arantxa Urunuela, Xiaojian Xu, and Patricia LoRusso. A phase i dose-escalation study of ly3405105, a covalent inhibitor of cyclin-dependent kinase 7, administered to patients with advanced solid tumors. The Oncologist, 29:e131-e140, Aug 2024. URL: https://doi.org/10.1093/oncolo/oyad215, doi:10.1093/oncolo/oyad215. This article has 23 citations.
(garralda2024aphasei pages 6-8): Elena Garralda, Alison M Schram, Philippe L Bedard, Gary K Schwartz, Eunice Yuen, Samuel C McNeely, Silvia Ribeiro, Jason Cunningham, Yi Wang, Arantxa Urunuela, Xiaojian Xu, and Patricia LoRusso. A phase i dose-escalation study of ly3405105, a covalent inhibitor of cyclin-dependent kinase 7, administered to patients with advanced solid tumors. The Oncologist, 29:e131-e140, Aug 2024. URL: https://doi.org/10.1093/oncolo/oyad215, doi:10.1093/oncolo/oyad215. This article has 23 citations.
(zhang2025recentadvancesin pages 1-2): Lingzhi Zhang, Shiqin Yang, Zhe Guan, Liangyu Lei, Tingting Zhang, Ye Zhang, Xiangyang Miao, and Shiqi Wu. Recent advances in development of cdk7 inhibitors and their clinical trials: a narrative review. Sep 2025. URL: https://doi.org/10.21037/tcr-2025-81, doi:10.21037/tcr-2025-81. This article has 5 citations.
(zhang2025recentadvancesin pages 10-12): Lingzhi Zhang, Shiqin Yang, Zhe Guan, Liangyu Lei, Tingting Zhang, Ye Zhang, Xiangyang Miao, and Shiqi Wu. Recent advances in development of cdk7 inhibitors and their clinical trials: a narrative review. Sep 2025. URL: https://doi.org/10.21037/tcr-2025-81, doi:10.21037/tcr-2025-81. This article has 5 citations.
(garralda2024aphasei pages 8-9): Elena Garralda, Alison M Schram, Philippe L Bedard, Gary K Schwartz, Eunice Yuen, Samuel C McNeely, Silvia Ribeiro, Jason Cunningham, Yi Wang, Arantxa Urunuela, Xiaojian Xu, and Patricia LoRusso. A phase i dose-escalation study of ly3405105, a covalent inhibitor of cyclin-dependent kinase 7, administered to patients with advanced solid tumors. The Oncologist, 29:e131-e140, Aug 2024. URL: https://doi.org/10.1093/oncolo/oyad215, doi:10.1093/oncolo/oyad215. This article has 23 citations.